Pharmacovigilance and Mechanistic Analysis of Adverse Reaction Differences Across EGFR Tyrosine Kinase Inhibitor Generations in Non-Small Cell Lung Cancer
- 1University of Birmingham
Abstract
BackgroundEpidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for EGFR-mutated non-small cell lung cancer (NSCLC) but have distinct toxicity profiles across generations.
AimsTo investigate relationships between EGFR-TKI physicochemical, pharmacokinetic and pharmacological properties and drug-specific adverse drug reactions (ADRs) using national and global pharmacovigilance data.
MethodsADRs for erlotinib, afatinib and osimertinib were extracted from the UK MHRA Yellow Card scheme and WHO VigiAccess. Disproportionality analysis used reporting odds ratios (RORs). Signals were defined as ROR [≥]2, lower 95% confidence interval >1 and [≥]3 cases. Drug properties were curated from ChEMBL, emc, SmPC and EMA sources.
ResultsVigiAccess contained 88,662 individual case safety reports (163,619 ADRs) and Yellow Card contained 752 reports (1,814 ADRs). Four System Organ Class (SOC) signals were identified in VigiAccess and three in Yellow Card, with five additional Yellow Card Preferred Term signals. Eye disorders showed the strongest consistent association with erlotinib (VigiAccess ROR 4.33; Yellow Card ROR 4.18). Osimertinib was associated with pneumonitis (ROR 7.67) and pulmonary embolism (ROR 3.94). Afatinib showed psychiatric disorder signals in both databases (ROR 3.2- 3.3) and diarrhoea (ROR 2.79). Neoplasm-related signals likely reflected confounding by indication.
ConclusionsEGFR-TKIs demonstrate generation-specific pharmacovigilance profiles. Integration with drug properties supports mechanistic plausibility for several signals, while the atypical afatinib psychiatric association warrants further investigation. Findings are hypothesis-generating and require confirmation in controlled observational or mechanistic studies.
What is already known about this subject?O_LIFirst-, second-and third-generation EGFR-TKIs (erlotinib, afatinib and osimertinib) are established treatments for EGFR-mutated NSCLC but are associated with distinct adverse drug reaction (ADR) profiles that differ across generations. C_LIO_LIKnown class-effect toxicities include dermatological, gastrointestinal, and ocular ADRs, attributed to EGFR inhibition in non-tumour epithelial tissues. C_LIO_LIPrior pharmacovigilance studies using the US FDA Adverse Event Reporting System (FAERS) have characterised EGFR-TKI safety signals, but UK-specific Yellow Card data have not been systematically analysed across all three generations, and the pharmacological basis for generation-specific differences remains incompletely understood. C_LI
What this study addsO_LIDual-database disproportionality analysis of MHRA Yellow Card and WHO VigiAccess data, using a pre-specified signal threshold (ROR [≥] 2, lower 95% CI > 1, n [≥] 3), confirmed generation-specific signals: eye disorders for erlotinib; psychiatric disorders and diarrhoea for afatinib; and pneumonitis and pulmonary embolism for osimertinib. C_LIO_LIIntegration of target potency (pIC50), ErbB family selectivity, blood brain barrier (BBB) penetration and CYP450 interaction data with the pharmacovigilance signals provides mechanistic plausibility, linking them to variations in binding reversibility, wild-type EGFR inhibition, and off-target kinase activity. C_LIO_LIApplying a pre-specified, conservative signal threshold distinguished genuine disproportionate signals from elevated but non-significant reporting and identified neoplasm-related findings as confounded by indication rather than true drug safety signals highlighting the importance of rigorous signal definition in oncology pharmacovigilance. C_LI
Related
- Proton Pump Inhibitor Use and Incident Epilepsy in the UK Biobank: Evidence From Pharmacovigilance and Multi‐Omics Analyses
- Hyperbolic heterogeneous graph learning for adverse drug reaction prediction, candidate prioritization, and pathway-based interpretation in pharmacovigilance
- Clinical characteristics and pharmacovigilance signals of immune checkpoint inhibitor-associated cystitis and ureteritis: analysis of FAERS reports and published cases
- BRAF and MEK inhibitors rechallenge after an adverse drug reaction in patients with cancer: A pharmacovigilance cohort study
- Are health sciences students prepared for pharmacovigilance? A nationwide study of knowledge and suspected adverse drug reaction reporting.
BibTeX
@misc{arojo2026pharmacovigilance,
title = {{Pharmacovigilance and Mechanistic Analysis of Adverse Reaction Differences Across EGFR Tyrosine Kinase Inhibitor Generations in Non-Small Cell Lung Cancer}},
author = {O. Arojo and A. M. Jones},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.16.26364955},
url = {https://www.medrxiv.org/content/10.64898/2026.10.16.26364955v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Pharmacovigilance and Mechanistic Analysis of Adverse Reaction Differences Across EGFR Tyrosine Kinase Inhibitor Generations in Non-Small Cell Lung Cancer
AU - O. Arojo
AU - A. M. Jones
PY - 2026
DA - 2026/10/16
PB - medRxiv
DO - 10.64898/2026.10.16.26364955
UR - https://www.medrxiv.org/content/10.64898/2026.10.16.26364955v1
AB - BackgroundEpidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for EGFR-mutated non-small cell lung cancer (NSCLC) but have distinct toxicity profiles across generations. AimsTo investigate relationships between EGFR-TKI physicochemical, pharmacokinetic and pharmacological properties and drug-specific adverse drug reactions (ADRs) using national and global pharmacovigilance data. MethodsADRs for erlotinib, afatinib and osimertinib were extracted from the UK MHRA Yellow Card scheme and WHO VigiAccess. Disproportionality analysis used reporting odds ratios (RORs). Signals were defined as ROR [≥]2, lower 95% confidence interval >1 and [≥]3 cases. Drug properties were curated from ChEMBL, emc, SmPC and EMA sources. ResultsVigiAccess contained 88,662 individual case safety reports (163,619 ADRs) and Yellow Card contained 752 reports (1,814 ADRs). Four System Organ Class (SOC) signals were identified in VigiAccess and three in Yellow Card, with five additional Yellow Card Preferred Term signals. Eye disorders showed the strongest consistent association with erlotinib (VigiAccess ROR 4.33; Yellow Card ROR 4.18). Osimertinib was associated with pneumonitis (ROR 7.67) and pulmonary embolism (ROR 3.94). Afatinib showed psychiatric disorder signals in both databases (ROR 3.2- 3.3) and diarrhoea (ROR 2.79). Neoplasm-related signals likely reflected confounding by indication. ConclusionsEGFR-TKIs demonstrate generation-specific pharmacovigilance profiles. Integration with drug properties supports mechanistic plausibility for several signals, while the atypical afatinib psychiatric association warrants further investigation. Findings are hypothesis-generating and require confirmation in controlled observational or mechanistic studies. What is already known about this subject?O_LIFirst-, second-and third-generation EGFR-TKIs (erlotinib, afatinib and osimertinib) are established treatments for EGFR-mutated NSCLC but are associated with distinct adverse drug reaction (ADR) profiles that differ across generations. C_LIO_LIKnown class-effect toxicities include dermatological, gastrointestinal, and ocular ADRs, attributed to EGFR inhibition in non-tumour epithelial tissues. C_LIO_LIPrior pharmacovigilance studies using the US FDA Adverse Event Reporting System (FAERS) have characterised EGFR-TKI safety signals, but UK-specific Yellow Card data have not been systematically analysed across all three generations, and the pharmacological basis for generation-specific differences remains incompletely understood. C_LI What this study addsO_LIDual-database disproportionality analysis of MHRA Yellow Card and WHO VigiAccess data, using a pre-specified signal threshold (ROR [≥] 2, lower 95% CI > 1, n [≥] 3), confirmed generation-specific signals: eye disorders for erlotinib; psychiatric disorders and diarrhoea for afatinib; and pneumonitis and pulmonary embolism for osimertinib. C_LIO_LIIntegration of target potency (pIC50), ErbB family selectivity, blood brain barrier (BBB) penetration and CYP450 interaction data with the pharmacovigilance signals provides mechanistic plausibility, linking them to variations in binding reversibility, wild-type EGFR inhibition, and off-target kinase activity. C_LIO_LIApplying a pre-specified, conservative signal threshold distinguished genuine disproportionate signals from elevated but non-significant reporting and identified neoplasm-related findings as confounded by indication rather than true drug safety signals highlighting the importance of rigorous signal definition in oncology pharmacovigilance. C_LI
ER -